Affilogic enters into a Research Collaboration and Licensing Agreement with Sanofi on Nanofitin-conjugated biotherapeutics

Affilogic announces the signature of a collaboration and license agreement with Sanofi for the development of Nanofitin®-conjugated biotherapeutics.

Nantes – June 22, 2016

In the framework of a research collaboration initiated in 2012, Affilogic applied its alternative scaffold technology, the Nanofitins®, for a joint discovery and development of Nanofitins® against an undisclosed target nominated by Sanofi. Affilogic selected Nanofitin® candidates from their proprietary libraries for subsequent conjugation to Sanofi proprietary molecules.

View article